O

Obio Technology Shanghai Corp Ltd
SSE:688238

Watchlist Manager
Obio Technology Shanghai Corp Ltd
SSE:688238
Watchlist
Price: 5.48 CNY -6.16% Market Closed
Market Cap: 3.5B CNY
Have any thoughts about
Obio Technology Shanghai Corp Ltd?
Write Note

Obio Technology Shanghai Corp Ltd
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Obio Technology Shanghai Corp Ltd
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
O
Obio Technology Shanghai Corp Ltd
SSE:688238
Accounts Payable
ÂĄ228.5m
CAGR 3-Years
150%
CAGR 5-Years
43%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Accounts Payable
ÂĄ2B
CAGR 3-Years
15%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Accounts Payable
ÂĄ503m
CAGR 3-Years
23%
CAGR 5-Years
33%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Accounts Payable
ÂĄ3.1B
CAGR 3-Years
79%
CAGR 5-Years
65%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Accounts Payable
ÂĄ227.1m
CAGR 3-Years
22%
CAGR 5-Years
46%
CAGR 10-Years
31%
W
WuXi XDC Cayman Inc
HKEX:2268
Accounts Payable
ÂĄ620.5m
CAGR 3-Years
417%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Obio Technology Shanghai Corp Ltd
Glance View

Market Cap
3.5B CNY
Industry
Life Sciences Tools & Services

Obio Technology Shanghai Corp. Ltd. engages in biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO service provision. The company is headquartered in Shanghai, Shanghai and currently employs 631 full-time employees. The company went IPO on 2022-03-22. The firm is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The firm mainly conducts business in the European and American markets and the domestic market.

Intrinsic Value
4.5 CNY
Overvaluation 18%
Intrinsic Value
Price
O

See Also

What is Obio Technology Shanghai Corp Ltd's Accounts Payable?
Accounts Payable
228.5m CNY

Based on the financial report for Dec 31, 2023, Obio Technology Shanghai Corp Ltd's Accounts Payable amounts to 228.5m CNY.

What is Obio Technology Shanghai Corp Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
43%

Over the last year, the Accounts Payable growth was 92%. The average annual Accounts Payable growth rates for Obio Technology Shanghai Corp Ltd have been 150% over the past three years , 43% over the past five years .

Back to Top